NCT01821781View on ClinicalTrials.gov

Immune Disorder HSCT Protocol

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Immune Deficiency DisordersSevere Combined ImmunodeficiencyChronic Granulomatous DiseaseX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeHyper-IgMDiGeorge SyndromeChediak-Higashi SyndromeCommon Variable Immune DeficiencyImmune Dysregulatory DisordersHemophagocytic LymphohistiocytosisIPEXAutoimmune Lymphoproliferative SyndromeX-linked Lymphoproliferative Syndrome
Interventions
DRUG

Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan

Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF

Trial Locations (1)

63110

RECRUITING

Washington University, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER